Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Aug
3
2023
The Secret to Success: Protecting Your Cannabis Trade Secrets Bradley Arant Boult Cummings LLP
Aug
2
2023
EC Committee Updates Guidance on the Safety Assessment of Nanomaterials in Cosmetics Bergeson & Campbell, P.C.
Aug
2
2023
AAFCO Approves New Model Pet Food and Specialty Pet Food Regulations for Pet Food Packaging Keller and Heckman LLP
Aug
2
2023
FDA Warns “Natural” Birth Control Company: Three Takeaways from the NOV Letter Mintz
Aug
1
2023
BETO Will Host Bioenergy Cybersecurity Workshop on September 11, 2023 Bergeson & Campbell, P.C.
Aug
1
2023
Lawsuit Against Starbucks Dismissed; Sanctions Against Plaintiff’s Attorney Considered Keller and Heckman LLP
Aug
1
2023
Unpacking Averages: Analyzing the Relationship Between MDRs and Recalls Epstein Becker & Green, P.C.
Aug
1
2023
Cancer Moonshot Initiative Adds Precision Surgery Effort Foley & Lardner LLP
Aug
1
2023
EPA Adds Nine PFAS Chemicals to The Toxics Release Inventory Reporting List Babst, Calland, Clements & Zomnir, P.C.
Aug
1
2023
Triaging Health Risks in the Cosmetic World: FDA Says Let’s Start with Tattoo Inks Polsinelli PC
Aug
1
2023
FDA’s LDT Proposed Rule Heads to the White House Epstein Becker & Green, P.C.
Aug
1
2023
Podcast: Inflation Reduction Act’s Drug Price Negotiation Provisions – What Now? – Diagnosing Health Care [Podcast] Epstein Becker & Green, P.C.
Aug
1
2023
Washington State Proposes Sweeping Changes to Key Greenhouse Gas Regulation Beveridge & Diamond PC
Jul
31
2023
UCB, Inc. v. Actavis Laboratories UT, Inc. No. 2021-1924, (Fed. Cir. Apr. 12, 2023) Sheppard, Mullin, Richter & Hampton LLP
Jul
31
2023
Proposed Class Action Dismissed Over Lack of Standing Keller and Heckman LLP
Jul
31
2023
The 2024 Proposed Hospital Outpatient Prospective Payment System and Physician Fee Schedule Rules: What Pharma Stakeholders Need to Know ArentFox Schiff LLP
Jul
31
2023
Bipartisan Group of Representatives Calls on EPA to Assess the Risks of PFAS in Fluorinated Containers Bergeson & Campbell, P.C.
Jul
31
2023
APHIS 2022 Impact Report Includes Summary of Biotechnology Activities Bergeson & Campbell, P.C.
Jul
28
2023
Will Mississippi’s List of Qualifying Conditions for Medical Cannabis Soon Be Expanded? Bradley Arant Boult Cummings LLP
Jul
28
2023
Amendment to House Bill Threatens Funding of Organic Standards Keller and Heckman LLP
Jul
27
2023
CMS Proposes Changes to Medicare Provider Enrollment Rules Polsinelli PC
Jul
27
2023
New Medicare Marketing Definition Squire Patton Boggs (US) LLP
Jul
27
2023
CMS Proposes Remedy for 340B-Acquired Drug Payment Policy for CY 2018-2022 Foley & Lardner LLP
Jul
27
2023
FDA Maintains Focus on “Intended Use” for Software-Enabled Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Jul
27
2023
FDA Denies Request to Reconsider Petition on Phthalates in Food Packaging Keller and Heckman LLP
Jul
26
2023
Bipartisan Legislation Would Strengthen USDA’s BioPreferred Program Bergeson & Campbell, P.C.
Jul
26
2023
July 2023 EU’s New HBER and Horizontal Guidelines: Main Changes Greenberg Traurig, LLP
Jul
25
2023
First Nonprescription Birth Control Pill Approved for Marketing by FDA: A Milestone for Reproductive Health Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins